Vicore has dosed the first patient in a study assessing the effect of its angiotensin II type 2 receptor agonist (ATRAG) C21 on endothelial dysfunction in type-2-diabetes-mellitus patients.
A simple, non-invasive FDA-approved technology, EndoPAT is used for identifying endothelial dysfunction in the proof-of-concept, double-blind, randomised, placebo-controlled, cross-over study.
Go deeper with GlobalData
It can also be used to investigate therapeutic efficacy in diseases driven by endothelial dysfunction and determine the active dose-range for new ATRAGs.
Vicore Pharma clinical operations vice-president Elin Rosendahl said: “Measuring endothelial dysfunction with the EndoPAT technology in drug trials is a cost-effective and robust method for early documentation of proof-of-concept in pulmonary, renal and vascular diseases.
“This has the potential to substantially shorten the timelines and decrease the risk in clinical development programmes.”
Endothelial dysfunction is a key driver of organ damage and is characterised by a proinflammatory and prothrombotic state with impaired microvascular blood flow.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataLund University experimental cardiology professor and trial principal investigator Jan Nilsson said: “Patients with diabetes mellitus have an increased risk of cardiovascular events and endothelial dysfunction is an important factor for this development.
“Treating endothelial dysfunction could be a major breakthrough in cardiovascular disease.”
Results from the trial are expected in the fourth quarter of this year.
